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We	 investigated	 the	 prognostic	 role	 of	 high	MICs	 for	 an-
tistaphylococcal	 agents	 in	 patients	 with	 methicillin-sensi-
tive	Staphylococcus aureus	 catheter-related	 bloodstream	
infection	 (MSSA	 CRBSI).	 We	 prospectively	 reviewed	 83	
episodes	 from	5	centers	 in	Spain	during	April	 2011–June	
2014	 that	 had	 optimized	 clinical	 management	 and	 ana-
lyzed	 the	 relationship	 between	E-test	MICs	 for	 vancomy-












Staphylococcus aureus bacteremia is an issue of con-cern because of high rates of illness and death for this 
condition (1). Some studies have identified high MICs for 
vancomycin (defined as an MIC >1.5 µg/mL by E-test) as 
a simple laboratory-based marker, which has been shown 
to be associated with a worse prognosis in methicillin-
resistant S. aureus (MRSA) bacteremia in terms of treat-
ment failure (2–4) and increased mortality rates (5,6). Such 
increased mortality rates associated with a high MIC for 
vancomycin has also been reported in methicillin-sensitive 
S. aureus (MSSA) bacteremia (7,8). However, the use of 
death as a study outcome and the fact that these studies 
were performed with patients with different sources of 
bacteremia make it difficult to interpret study results. Such 
findings could not be confirmed in large cohorts of patients 
with MRSA (9–11) or MSSA (12) bacteremia from differ-
ent sources.
To avoid these confounding factors, we focused on 
a more homogeneous population of patients with MSSA 
catheter-related bloodstream infection (MSSA CRBSI) 
for whom specific efforts were devoted to optimize clini-
cal management. In a previous retrospective study, we 
observed that high MICs for vancomycin were associated 
with development of complicated MSSA CRBSI, regard-
less of the initial antimicrobial drug therapy used (vanco-
mycin or β-lactams), which suggested that intrinsic char-
acteristics of these strains might explain their pathogenic 
role in development of complicated bacteremia (13). We 
designed this multicenter prospective study to confirm the 
prognostic role of high MICs for vancomycin and to ex-
plore if increased MICs for other antistaphylococcal agents 
could also influence the risk for developing complicated 
MSSA CRBSI.
Materials and Methods
Study Design and Setting
We conducted a prospective, observational, multicenter 
study during April 2011–June 2014 in 5 hospitals in Spain 
in which we included patients given a diagnosis of MSSA 
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CRBSI according to standard a definition (14) that fulfilled 
5 criteria: 1) age >18 years and a life expectancy >7 days; 
2) no use of daptomycin within the 3 months preceding 
the incident MSSA CRBSI episode; 3) removal of the in-
travascular catheter suspected to be the source of CRBSI 
within a maximum of 72 hours from sampling of the first 
blood cultures yielding MSSA; 4) a maximum of 72 hours 
of treatment with glycopeptides; and 5) at least the first 
blood culture isolate available for microbiological analysis. 
All included patients signed a study-specific informed con-
sent form. The study was approved by the ethics research 
boards at all participating centers.
Management of MSSA CRBSI
Although the nature of the study was not interventional, 
the adherence to evidence-based quality-of-care measures 
was strongly encouraged among participating investigators 
to optimize the therapeutic management of MSSA CRBSI. 
These measures were extraction of follow-up blood cul-
tures, ordering echocardiography or venous Doppler ul-
trasound examination for patients with clinical indication, 
early use of intravenous cloxacillin or other highly effective 
antimicrobial drugs for treatment of for MSSA as definitive 
therapy, and adjustment of treatment duration according to 
the complexity of the infection.
Definitions
Recorded clinical variables were age; site of acquisition 
of infection; concurrent conditions, as assessed by the Co-
morbidity Index of Charlson et al. (15); prognosis of the 
underlying disease (classified according to the McCabe and 
Jackson modified criteria as rapidly fatal [when death was 
expected within 3 months], ultimately fatal [when death 
was expected within a period of >3 months but <5 years] 
and nonfatal [when life expectancy was >5 years]) (16); 
type of intravenous catheter; timing of catheter removal; 
treatment administered; duration of fever; duration of bac-
teremia; Pitt bacteremia score (17); development of septic 
shock; endovascular infection or complicated bacteremia 
(defined below); and all-cause and MSSA CRBSI−attribut-
able mortality rates at 30 days. MSSA CRBSI−attributable 
deaths at 30 days were identified as per the clinical judg-
ment of the investigator.
Antimicrobial drugs were classified within 1 of the 
following mutually excluding categories: glycopeptides; 
daptomycin; antistaphylococcal β-lactams (parenteral 
cloxacillin, cefazolin or other active β-lactams [including 
parenteral amoxicillin/clavulanate, piperacillin/tazobac-
tam, imipenem, or meropenem]); non−β-lactam agents 
with in vitro activity against MSSA (antistaphylococ-
cal quinolones, tigecycline, or linezolid); and noneffec-
tive agents. Timing to initiation of antimicrobial drug 
therapy and duration of treatment were also recorded. 
Empiric therapy was defined as therapy administered be-
fore identification and antimicrobial susceptibility testing 
of the isolate. Complicated bacteremia (study outcome) 
was defined by 1 of 5 events occurring after the incident 
episode of MSSA CRBSI: 1) development of endocardi-
tis (defined according to modified Duke criteria) (18); 2) 
septic thrombophlebitis (defined by persistent MSSA bac-
teremia for >72 hours after the initiation of active therapy 
associated to the documentation of a thrombus at the site 
of catheter insertion); 3) septic metastatic infection, in-
cluding arthritis, spondylitis, infections involving vascu-
lar or osteoarticular prostheses (excluding intravascular 
catheter) or end-organ hematogenous seeding to other lo-
cations remote from the primary focus; 4) persistent bac-
teremia for >72 hours; or 5) persistent fever for >4 days 
after extraction of the first blood culture yielding MSSA, 
provided that alternative causes had been reasonably 
excluded (19).
Microbiological Methods
Blood cultures were processed and isolates were identi-
fied according to standard techniques at each participat-
ing center. The first MSSA isolate from each patient was 
stored at –80°C until analysis and sent to the central refer-
ence laboratory (Department of Microbiology, University 
Hospital 12 de Octubre, Madrid, Spain). We subsequently 
subcultured strains twice and performed antimicrobial sus-
ceptibility testing by using the E-test method according to 
manufacturer’s recommendations (AB bioMérieux, Solna, 
Sweden). We tested vancomycin, daptomycin, oxacillin, 
and linezolid. In addition, the E-test macromethod was per-
formed to screen for heteroresistant vancomycin-interme-
diate S. aureus (hVISA) (20). All the plates were visually 
read throughout the entire study period by 2 independent 
observers, who were blinded to each other and to the clini-
cal outcomes. Interobserver discrepancies were resolved by 
reevaluation and a consensus decision.
Statistical Analysis
We used the Student unpaired t-test to compare normally 
distributed continuous variables, the Mann-Whitney U test 
to compare continuous variables with non-normal distribu-
tion, and the χ2 and Fisher exact tests to compare propor-
tions as appropriate. Areas under receiving operating char-
acteristic curves for MICs for selected antistaphylococcal 
agents (on the basis of their discriminative value at the uni-
variate comparisons) were plotted to select the optimal cut-
off value in terms of sensitivity (S) and specificity (Sp) to 
distinguish between patients with or without complicated 
bacteremia by means of the Youden’s J statistic (J = S + Sp 
−1). We calculated the Pearson correlation coefficient (r) to 
assess the strength of the linear relationship among E-test 
MICs for daptomycin and vancomycin.
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To test the effect of high MICs for antistaphylococ-
cal agents and other clinical variables on the occurrence of 
complicated MSSA CRBSI, we plotted event-free Kaplan-
Meier survival curves and performed comparisons between 
groups by using the log-rank test. Statistically relevant 
variables (p<0.10) at the univariate level were entered into 
multivariate Cox proportional hazard models with a back-
ward stepwise selection, and hazard ratios (HRs) with 95% 
CIs were estimated. Some variables considered clinically 
relevant were also forced into the models regardless of their 
univariate p values. All statistical tests were 2-tailed, and 
the threshold of statistical significance was set at p<0.05. 
We used statistical software SPSS version 20.0 (SPSS, 
Inc., Chicago, IL, USA) to perform calculations of differ-
ent analysis and generated graphics by using Prism version 
6.0 (GraphPad Software Inc., La Jolla, CA, USA). Vari-
ables with an unacceptable proportion of missing values 
(>30%) were excluded from the analysis.
Results
Study Population and Outcome
Of 108 patients initially recruited, 19 were excluded be-
cause they did not fulfill inclusion criteria after revision of 
the clinical charts (13 had received >72 hours of treatment 
with vancomycin and 6 had had a delay of >3 days in cath-
eter removal). An additional 6 patients cases were excluded 
because of inability to recover the MSSA strain for micro-
biological analysis. Therefore, we included 83 patients in 
the final analysis; median follow-up was 479 days (range 
5 days–1,014 days). No variables were excluded because 
of missing data. None of the included patients had received 
vancomycin, daptomycin, oxacillin, or linezolid within the 
3 months preceding the incidence MSSA CRBSI episode.
We compared the main demographic and clinical 
characteristics of the 83 patients in the final cohort (Ta-
ble 1). Catheter removal was performed for all patients 
within the first 72 hours from sampling of the first blood 
cultures and, in most (75 [90.6%]) patients, within the 
first 48 hours. Antistaphylococcal β-lactams were used 
as empiric therapy in 43 patients (51.8%), glycopeptides 
in 32 (38.5%), and daptomycin in 17 (20.4%). Combined 
therapy was used for 25 (31.1%) patients. Twelve (14.5%) 
patients received no empiric therapy or the regimen ad-
ministered was based on antimicrobial drugs with no in 
vitro activity against MSSA. For all patients who received 
daptomycin, the dose used was >6 mg/kg/day (range 6−10 
mg/kg/day). Venous Doppler ultrasound examination and 
echocardiogram were performed for 41 (49.5%) and 61 pa-
tients (73.5%), respectively.
Complicated MSSA CRBSI developed in 26 patients 
(31.3%) at a median of 4 days (interquartile range [IQR] 
1–26 days) after sampling of blood cultures. No patients 
had late complications (i.e., >30 days). Septic thrombo-
phlebitis was the most frequent complication (10 patients 
[12%]), followed by right-sided endocarditis (2 cases 
[2.4%]), hematogenous osteoarticular infection (2 cases 
[2.4%]), and pulmonary emboli (2 cases [2.4%]) (online 
Technical Appendix Table 1, http://wwwnc.cdc.gov/EID/
article/22/6/15-1709-Techapp1.pdf). All-cause and MSSA 
CRBSI−attributable 30-day mortality rates were 12.0% and 
2.4%, respectively.
Correlation between MICs and Outcome
All strains were sensitive to all antimicrobial drugs tested. 
None of the isolates had the hVISA phenotype. The 50% 
MIC and 90% MIC and distribution ranges values were 0.5 
µg/mL and 0.75 µg/mL (range 0.5–0.75 µg/mL) for cloxa-
cillin, 1.5 µg/mL and 2 µg/mL (range 0.5–2.5 µg/mL) for 
vancomycin, 0.38 µg/mL and 0.75 µg/mL (range 0.125–
0.94 µg/mL) for daptomycin, and 1 µg/mL and 1.5 µg/mL 
(range 0.25–2 µg/mL) for linezolid.
We compiled a comparative description of geomet-
ric means of MICs determined by E-test for vancomycin, 
daptomycin, oxacillin, and linezolid among isolates from 
patients with or without complicated bacteremia (Table 2). 
We observed that the MICs for vancomycin and daptomy-
cin were higher for isolates from patients in whom compli-
cated bacteremia developed.
We subsequently performed an exploratory area un-
der receiving operating characteristic curve analysis to 
establish the optimal cutoff point for the daptomycin MIC 
with the best discriminatory capacity to predict devel-
opment of complicated bacteremia. An MIC for dapto-
mycin of 0.5 µg/mL was selected (online Technical Ap-
pendix Figure 1). This approach also confirmed that 1.5 
µg/mL was the optimal cutoff point for the vancomycin 
MIC (online Technical Appendix Figure 2). A total of 43 
strains (41.8%) had a vancomycin MIC >1.5, µg/mL and 
13 (15.7%) had a daptomycin MIC >0.5 µg/mL. On the 
basis of these thresholds, 11 (84.6%) of 13 isolates with 
high MICs for daptomycin also showed high MICs for 
vancomycin, and we found a moderate positive correla-
tion between these variables (r = 0.21, p = 0.05) (online 
Technical Appendix Figure 3). The percentage of MSSA 
strains with high MICs for vancomycin or daptomycin 
was higher in the group of patients with complicated bac-
teremia (Table 2). Strains isolated from all the patients in 
whom septic thrombophlebitis developed had high MICs 
for vancomycin or daptomycin.
We compared clinical characteristics of patients ac-
cording to MICs for vancomycin or daptomycin (Table 
3). Rates of complicated MSSA CRBSI were significantly 
higher among patients with episodes caused by strains with 
MICs for vancomycin (42% vs. 20%; p = 0.05) or dapto-
mycin (69.2% vs. 24.3%; p = 0.004) than for those with 
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episodes caused by strains with lower MICs. Strains with 
high MICs for vancomycin were not associated with higher 
rates of severe sepsis or septic shock at bacteremia onset, 
or with increased all-cause or attributable mortality rates. 
Conversely, we found that high MICs for daptomycin were 










Recruiting center  
 1 32	(38.6) 
 2 19	(22.9) 
 3 2	(2.4) 
 4 12	(14.5) 
 5 18	(21.7) 
Prognosis	of	underlying	disease  
 Not	fatal 31	(37.3) 
 Fatal 44	(53.0) 
 Rapidly	fatal 8	(9.6) 
Charlson	comorbidity	index 3.7	±	2.3 
Previous	conditions  
 Diabetes 32	(38.6) 
 Malignancy 45	(54.2) 
 Valvular	prosthesis 1	(1.2) 
 Ostheoarticular	prosthesis 3	(3.6) 
 Renal	failure	requiring	hemodialysis 10	(12) 
Type	of	intravascular	catheter  
 Peripheral	venous 32	(38.6) 
 Nontunneled (temporary)	central	venous 25	(30.1) 
 Peripherally	inserted	central 10	(12) 




 Glycopeptides 32	(38.5) 
 Antistaphylococcal	β-lactams‡ 43	(51.8) 
 Other	antistaphylococcal	antimicrobial	drugs 4	(4.8) 
 Daptomycin 17	(20.4) 
 None	or	noneffective	antimicrobial	drugs 12	(14.5) 
Antimicrobial	regimen  
 Glycopeptides	followed	by	antistaphylococcal	β-lactam 25	(30.1) 
 Only	antistaphylococcal	β-lactams 30	(36.1) 
 Daptomycin	followed	by	antistaphylococcal	β-lactam 12	(14.5) 
 Only	daptomycin 1	(1.2) 
 Glycopeptides	followed	by	daptomycin	plus	antistaphylococcal	β-lactam 7	(8.4) 
 Daptomycin	plus	antistaphylococcal	β-lactam 7	(8.4) 
 Other 1	(1.2) 
Timing	of	catheter	removal  
 Same	day	or	before	sampling	first	blood	cultures 47	(56.6) 
 1	day	after	sampling 12	(14.5) 
 2	days	after	sampling 17	(20.5) 
 3	days	after	sampling 7	(8.4) 
Venous	Doppler ultrasound	examination 41	(49.5) 
Echocardiogram 61	(73.5) 
 Complicated	MSSA	CRBSI 26	(31.3) 
 Persistent	fever	>4	d§ 11	(13.3) 
 Persistent	bacteremia	>72	h¶ 6	(7.2) 
 Septic	thrombophlebitis 10	(12) 
 Endocarditis 2	(2.4) 
 Hematogenous	osteoarticular infection 2	(2.4) 
 Pulmonary	emboli 2	(2.4) 
All-cause	deaths	at	30	days 10	(12) 
MSSA	CRBSIattributable	deaths	at	30	days 2	(2.4) 







(i.e., severe sepsis or septic shock) than among remaining 
episodes (46.2% vs. 15.7%, p = 0.02). However, no effect 
on mortality rates was observed.
Risk Factors for Development of  
Complicated Bacteremia
We compared clinical characteristics of patients with or 
without complicated bacteremia (Table 4). Most (65.4%) 
patients with complicated cases were given a diagnosis at 
1 recruiting center. Such an imbalance might be partially 
explained by the fact that such a center was the study pro-
moter and the largest center at which the greatest diagnos-
tic efforts were made. The probability of remaining free of 
complicated bacteremia at day 30 was significantly lower 
for patients with MSSA CRBSI caused by isolates with 
daptomycin MICs >0.5 µg/mL (33. 3% vs. 75%; log-rank 
test p = 0.002) and isolates with vancomycin MICs >1.5 
µg/mL (59.2% vs. 79.6%; log-rank test p = 0.02) (Figure).
Because of low number of patients with complicated 
bacteremia (26 episodes), we could not assess the potential 
effect of MICs by performing a single logistic regression 
model adjusted for all the covariates found to be signifi-
cant by univariate analysis. We alternatively attempted an 
exploratory approach based on different models. We used 
Cox regression models that incorporated a maximum of 3 
variables at a time, always including the recruiting center 
as a potential confounder (Table 5; online Technical Ap-
pendix Table 2). The presence of high MICs for vanco-
mycin (minimum adjusted HR 2.4, 95% CI 1.2–5.5) and 
daptomycin (minimum adjusted HR 2.4, 95% CI 1.1–5.9) 
were kept as independent risk factors for development of 
complicated MSSA CRBSI in all models.
We performed a sensitivity analysis by restricting the 
study outcome to the occurrence of septic thrombophle-
bitis. These associations remained essentially unchanged, 
and we observed even higher HRs (minimum adjusted HR 
for vancomycin MIC 6.0 [95% CI 0.7–52.2]; minimum 
adjusted HR for daptomycin MIC 5.5 [95% CI 1.3–22.5]) 
(online Technical Appendix Tables 2, 3).
Discussion
The aim of our study was to investigate the potential role 
of high MICs for vancomycin and other antistaphylococcal 
agents in predicting the risk for complications in a selected 
cohort of patients with MSSA CRBSI. We investigated this 
role after controlling for other well-defined prognostic fac-
tors, such as timing of catheter removal or appropriateness 
of empiric therapy.
We found a correlation between high MICs for vanco-
mycin (>1.5 µg/mL) or daptomycin (>0.5 µg/mL) and an 
increased incidence of complicated bacteremia, particular-
ly in terms of local endovascular complications represent-
ed by septic thrombophlebitis. Venous Doppler ultrasound 
examination was performed for only 50% of patients. Not-
withstanding this potential drawback, we included in the 
definition of the study outcome the presence of persistent 
bacteremia in the absence of proven hematogenous spread 
to distant locations. This criterion might act as an appropri-
ate clinical surrogate for identifying potential cases of sep-
tic thrombophlebitis that could have eventually remained 
undiagnosed.
Results confirm those obtained in our previous single-
center retrospective study (13), in which we demonstrated 
that MSSA strains with vancomycin MICs >1.5 µg/mL 
were associated with a >2-fold increase in risk for develop-
ment of complicated bacteremia and, specifically, a >6-fold 
increase in the risk for development of septic thrombophle-
bitis. In both studies, and in contrast to other authors who 
evaluated MSSA bacteremia from different sources (7), 
including patients with endocarditis (8), we did not find 
any apparent effect of increased MICs on sepsis severity 
or risk for death. The relatively low 30-day mortality rate 
for our selected cohort could partially account for this dis-
crepancy. However, López-Cortés et al. (12) did not dem-
onstrate any apparent effect of MICs for vancomycin on 
mortality rates in a recent study of a nonselected cohort 
of patients with MSSA bacteremia. These authors also re-
ported an increased incidence of septic thrombophlebitis 











MIC,	g/mL   
 Vancomycin 1.2	±	0.4† 1.5	±	0.48† 
 Oxacillin 0.49	±	0.27 0.51	±	0.2 
 Daptomycin 0.4	±	0.16† 0.5	±	0.2† 
 Linezolid 1.08	±	0.13 1.05	±	0.08 
Frequency   
 Vancomycin	MIC	>1.5	g/mL 25	(43.9)† 18	(69.2)† 
 Daptomycin	MIC	>0.5	g/mL 4	(7.0)† 9	(34.6)† 
 Vancomycin	MIC	>1.5	g/mL	or	daptomycin	MIC	>0.5	g/mL 26	(45.6)† 19	(73.1)† 





with high MICs for vancomycin. This combined evidence 
suggests that the theoretically increased pathogenicity of 
these strains might exert a local vascular effect but does 
necessarily imply a higher risk for severe sepsis or death.
The role of MICs for daptomycin as a prognostic 
marker in episodes of MSSA bacteremia has not been ex-
tensively investigated. In a study by Cervera et al., which 
included only patients with endocarditis caused by MSSA, 
MICs for daptomycin were not related to increased mortal-
ity rates (8). We have established a cutoff value for the 
MIC for daptomycin (>0.5 µg/mL) that also identified pa-
tients with an increased risk for development of complicat-
ed MSSA CRBSI, particularly septic thrombophlebitis. In 
accordance with lack of a correlation for the MIC for van-
comycin, mortality rates did not differ according to MICs 











<1.5,	n	=	40 >1.5,	n	=	43 p	value <0.5,	n	=	70 >0.5,	n	=	13 p	value 
Age,	y 61.9	±	16.0 59.9	±	19.0 0.42  60.2	±	17.3 63.8	±	21.0 0.5 
Male	sex 23	(57.5) 26	(60.5) 0.42  41	(58.6) 8	(61.5) 0.4 
Prognosis	of	underlying	disease        
 Not	fatal 18	(45.0) 13	(30.2) 0.3  24	(34.3) 7	(53.8) 0.3 
 Fatal 17(42.5) 27	(62.8) 0.1  39	(55.7) 5	(38.5) 0.4 
 Rapidly	fatal 5	(12.5) 3	(6.9) 0.6  7	(10.0) 1	(7.7) 0.8 
Charlson comorbidity	index 3.5	±	2.6 4.0	±	2.1 0.31  3.7	±	2.3 3.5	±	2.1 0.9 
Previous	conditions        
 Diabetes 20	(50.0) 12	(27.9) 0.06  28	(40) 4	(30.8) 0.6 
 Malignancy 17	(42.5) 28	(65.1) 0.12  37	(52.9) 8	(61.5) 0.5 
 Valvular	prosthesis 0	(0.0) 1	(2.3) 0.9  1	(1.4) 0	(0.0) 0.9 
 Ostheoarticular	prosthesis 1	(2.5) 2	(4.7) 0.79  2	(2.9) 1	(7.7) 0.6 
 Renal	failure	requiring	hemodialysis 7	(17.5) 3	(6.9) 0.2  9	(12.9) 1	(7.7) 0.5 
Type	of	intravascular	catheter        
 Peripheral	venous 17	(42.5) 15	(34.9) 0.71  28	(40) 4	(30.8) 0.7 
 Nontunneled	(temporary)	central	venous 13	(32.5) 12	(27.9) 0.82  19	(27.1) 6	(46.2) 0.3 
 Peripherally	inserted	central 5	(12.5) 5	(11.6) 0.76  10	(14.3) 0	(0.0) 0.3 
 Permanent	central	venous 5	(12.5) 11	(25.6) 0.2  13	(18.6) 3	(23.1) 0.6 
Pitt	score	at	bacteremia	onset 1.5	±	1.7 1.1	±	1.4 0.9  1.3	±	1.7 1.2	±	1.0 0.9 
Severe	sepsis	or	septic	shock 11	(27.5) 6	(13.9) 0.2  11	(15.7) 6	(46.2) 0.02 
Empiric	treatment	including†        
  Glycopeptides 16	(40.0) 16	(37.2) 0.7  27	(38.5) 5	(38.4) 0.7 
  Antistaphylococcal	β-lactams‡ 21	(52.5) 22	(51.1) 0.9  37	(52.8) 6	(46.1) 0.7 
  Other	antistaphylococcal	antimicrobial	drugs 1	(2.5) 3	(6.9) 0.7  4	(5.7) 0	(0.0) 0.8 
  Daptomycin 7	(17.5) 10	(23.2) 0.8  13	(18.5) 4	(30.7) 0.5 
  None	or	noneffective	antimicrobial	drugs 7	(17.5) 5	(11.6) 0.8  10	(14.3) 2	(15.4) 0.8 
Antimicrobial	regimen        
 Glycopeptides	followed	by	antistaphylococcal	 
 β-lactam 
11	(27.5) 14	(32.6) 0.7  21	(30.0) 4	(30.8) 0.9 
 Only	antistaphylococcal	β-lactams 14	(35) 16	(37.2) 0.8  26	(37.1) 4	(30.8) 0.8 
 Daptomycin	followed	by	antistaphylococcal	β-lactam 3	(7.5) 9	(20.9) 0.16  8	(11.4) 4	(30.8) 0.2 
 Only	daptomycin 1	(2.5) 0	(0.0) 0.9  1	(1.5) 0	(0.0) 0.9 
 Glycopeptides	followed	by	daptomycin	plus	 
 antistaphylococcal	β-lactam 
6	(15.0) 1	(2.3) 0.09  6	(8.6) 1	(7.7) 0.9 
 Daptomycin	plus	antistaphylococcal	β-lactam 4	(10.0) 3	(6.9) 0.8  7	(10) 0	(0.0) 0.5 
 Other 1	(1.25) 0	(0.0) 0.6  1	(2.5) 0	(0.0) 0.7 
Timing	of	catheter	removal        
 Same	day	or	before	sampling	first	blood	cultures 28	(70.0) 19	(44.2) 0.03  41	(58.6) 6	(46.2) 0.7 
 1	day	after	sampling 6	(15.0) 6	(13.9) 0.9  10	(14.3) 2	(15.4) 0.9 
 2	days	after	sampling 5	(12.5) 12	(27.9) 0.1  12	(17.1) 5	(38.5) 0.2 
 3	days	after	sampling 1	(2.5) 6	(13.9) 0.1  7	(10.0) 0	(0.0) 0.6 
Complicated	MSSA	CRBSI 8	(20.0) 18	(41.9) 0.05  17	(24.3) 9	(69.2) 0.004 
 Persistent	fever	for	>4	d 3	(7.5) 8	(18.6) 0.2  9	(12.9) 2	(15.4) 0.8 
 Persistent	bacteremia	for	>72	h 2	(5.0) 4	(9.3) 0.7  5	(7.1) 1	(7.7) 0.9 
 Septic	thrombophlebitis 1	(2.5) 9	(20.9) 0.02  4	(5.7) 6	(46.2) <0.0001 
 Endocarditis 1	(2.5) 1	(2.3) 0.9  2	(2.9) 0	(0.0) 0.9 
 Hematogenous	osteoarticular	infection 1	(2.5) 1	(2.3) 0.9  1	(1.4) 1	(7.7) 0.5 
 Pulmonary	emboli 2	(4.7) 0	(0.0) 0.3  2	(2.9) 0	(0.0) 0.6 
All-cause	deaths	at	30	days 6	(15.0) 4	(9.3) 0.5  9	(12.9) 1	(7.7) 0.5 
MSSA	CRBSI–attributable	deaths	at	30	days 1	(2.5) 1	(2.3) 0.4  2	(2.9) 0	(0.0) 0.4 
*Values	are	geometric	mean	 SD	or	no.	(%).	MSSA	CRBSI:	methicillin-sensitive	Staphylococcus aureus catheter-related	bloodstream	infection. 
†Some	patients	could	be	included	in	>1	category. 
‡Parenteral cloxacillin, cefazolin, amoxicillin/clavulanate, piperacillin/tazobactam, imipenem, or	meropenem. 
 
	Catheter-Related	Bloodstream	Infections	with	MSSA
simultaneously high MICs for vancomycin and daptomy-
cin, and multivariate analysis demonstrated that both vari-
ables had an independent effect on the risk for development 
of complicated MSSA CRBSI.
It has been reported that MRSA isolates, mostly hVI-
SA isolates, with higher MICs for vancomycin also have 
increased MICs for daptomycin (21–24). However, other 
studies have failed to confirm such an association (25–27). 
Pillai et al. found that some MSSA strains obtained from 
a patient with persistent bacteremia treated with vanco-
mycin showed increasing MICs for daptomycin (28). In 
vitro studies suggested that patients infected with MSSA 
strains that have high MICs for vancomycin could have 
poor responses not only to vancomycin (29) but also to 
other antistaphylococcal agents, such as cloxacillin or 









p	value No,	n	=	5 Yes,	n	=	26 
Age,	y 61.4	±	16.0 59.3	±	21.0 0.1 
Male	sex 32	(56.1) 17	(65.4) 0.5 
Recruiting center    
 1 15	(26.3) 17	(65.4) 0.01 
 2 14	(24.6) 5	(19.2) 0.8 
 3 2	(3.5) 0	(0.0) 1.0 
 4 11	(19.3) 1	(3.8) 0.2 
 5 15	(26.3) 3	(11.5) 0.2 
Prognosis	of	underlying	disease    
 Not	fatal 24	(42.1) 7	(26.9) 0.2 
 Fatal 29	(50.9) 15	(57.7) 0.6 
 Rapidly	fatal 4	(7.0) 4	(15.4) 0.3 
Charlson	comorbidity	index 3.6	±	2.4 1.9	±	1.9 0.3 
Previous	conditions    
 Diabetes 20	(35.1) 12	(46.2) 0.3 
 Malignancy 29	(50.9) 16	(61.5) 0.6 
 Valvular	prosthesis 1	(1.8) 0	(0.0) 1.0 
 Ostheoarticular	prosthesis 1	(1.8) 2	(7.7) 0.2 
 Renal	failure	requiring	hemodialysis 7	(12.3) 3	(11.5) 1.0 
Type	of	intravascular	catheter    
 Peripheral	venous 23	(40.4) 9	(34.6) 0.8 
 Nontunneled	(temporary)	central	venous 17	(29.8) 8	(30.8) 1.0 
 Peripherally	inserted	central	 7	(12.3) 3	(11.5) 1.0 
 Permanent	central	venous 10	(17.5) 6	(23.1) 0.6 
Pitt	score	at	bacteremia	onset 1.1	±	1.4 1.7	±	1.9 0.1 
Severe	sepsis	or	septic	shock 11	(19.3) 6	(23.1) 0.3 
Empiric	treatment	including†    
 Glycopeptides 24	(42) 8	(30.7) 0.4 
 Antistaphylococcal	β-lactams‡ 31	(54.3) 12	(46.1) 0.6 
 Other	antistaphylococcal	antimicrobial	drugs 1	(1.7) 3	(11.5) 0.2 
 Daptomycin 8	(14) 9	(34.6) 0.06 
 Daptomycin	monotherapy 5	(8.8) 8	(30.8) 0.02 
 None	or	noneffective	antimicrobial	drugs 10	(17.5) 2	(7.7) 0.4 
Antimicrobial	regimen    
 Glycopeptides	followed	by	antistaphylococcal	β-lactam 19	(33.3) 6	(23.1) 0.4 
 Only	antistaphylococcal	β-lactams 23	(40.4) 7	(26.9) 0.3 
 Daptomycin	followed	by	antistaphylococcal	β-lactam 4	(7.0) 8	(30.8) 0.01 
 Only	daptomycin 1	(1.8) 0	(0.0) 1.0 
 Glycopeptides	followed	by	daptomycin	plus	antistaphylococcal	β-lactam 6	(10.5) 1	(3.8) 0.4 
 Daptomycin	plus	antistaphylococcal	β-lactam 3	(5.3) 4	(15.4) 0.2 
 Other 1	(1.8) 0	(0.0) 1.0 
Timing	of	catheter	removal    
 Same	day	or	before	of	sampling	first	blood	cultures 36	(63.2) 11	(42.3) 0.1 
 1	day	after	sampling 6	(10.5) 6	(23.1) 0.1 
 2	days	after	sampling 10	(17.5) 7	(26.9) 0.4 
 3	days	after	sampling 5	(8.8) 2	(7.7) 1.0 
Venous	Doppler	ultrasound	examination 21	(36.8) 20	(76.9) 0.001 
Echocardiogram 36	(63.2) 25	(96.2) 0.01 
All-cause	deaths	at	30	days 7	(12.3) 3	(11.5) 1.0 
MSSA	CRBSI–attributable	deaths	at	30	days  0	(0.0) 2	(7.7) 0.09 





resistance was associated with increased thickness of 
bacterial cell wall peptidoglycan and a slightly delayed 
transition to the postexponential growth phase because of 
alterations in bacterial metabolism (31). These findings 
suggest a deleterious fitness cost in terms of invasiveness 
(31) but also a blockage in the adhesive phase of S. aureus 
that might be linked to an increased trend in local compli-
cations. High MICs for vancomycin in isolates with the 
hVISA phenotype have been shown to be associated with 
increased persistence, rather than increased mortality rates 
and sepsis in patients (32). Although we did not detect any 
hVISA isolates in our study, we postulate that a high MIC 
for vancomycin could be an essential step in acquisition 
of this phenotype, and that this step might be the common 
underlying pathogenic mechanism.
Apart from the limited number of events (which pre-
vented including all explanatory variables into a single 
multivariate model), some limitations of the study also 
deserve specific consideration. Despite its multicenter 
nature, 1 specific participating center provided most of 
the results because this center recruited most of the pa-
tients and most patients who had complicated bacteremia. 
However, all multivariate models were adjusted by the 
recruiting center to minimize such potential bias. Anti-
microbial drug susceptibility testing was not performed 
in parallel with the reference broth microdilution method, 
which could have enabled us to confirm the poor correla-
tion previously reported between this technique and the 
E-test (11).
Conversely, interobserver reproducibility of the E-
test for assessing vancomycin MICs has been recently 
questioned (33). In our study, MIC testing was performed 
over a continuous period, and E-test results were read 
by 2 independent observers who were blinded to patient 
outcome, an approach that theoretically would reduce in-
traassay variability and facilitate interpretation of results. 
Finally, real-life applicability of our findings and potential 
prognostic value of performing E-tests for daptomycin for 
all MSSA isolates from patients with CRBSI remain to 
be established with support of cost-effectiveness analysis. 
Although we did not specifically address some variables 
that had been postulated to be related with higher MICs 
for vancomycin or daptomycin, such as inoculum size 
(34) or use of suboptimal dosing of daptomycin for cases 
of persistent bacteremia (35), we set a priori inclusion 
criteria to homogenize the clinical management of pa-
tients analyzed (including uniform dosing of daptomycin 
and vancomycin).
In summary, our data suggest that patients with MSSA 
CRBSI caused by strains with MICs >1.5 µg/mL for vanco-
mycin or >0.5 µg/mL for daptomycin determined by E-test 
are more prone to show development of complications, par-
ticularly septic thrombophlebitis. However, these patients 
do not appear to have an increased risk for severe sepsis or 
death. On the basis of these preliminary findings, patients 
with CRBSI cause by MSSA isolates with high MICs for 
vancomycin or daptomycin should be carefully evaluated 
to exclude local complications and eventually individualize 
duration of therapy. These prospects would merit confirma-
tion in future intervention studies.
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Table 5. Univariate	and	multivariate	analyses	of	risk	factors	for	development	of	complicated	methicillin-sensitive Staphylococcus 
aureus catheter-related	bloodstream	infection* 
Variable Univariate,	HR	(95%	CI)	 Multivariate,	HR	(95%	CI)† 
Recruiting	center	1 3.6	(1.6–8.1) – 
Any	daptomycin-containing	empiric	therapy 2.5	(1.1–5.7) – 
Daptomycin	monotherapy	as	empiric	therapy 3.1	(1.3–7.1) – 
Vancomycin	MIC	>1.5	g/mL 2.6	(1.1–5.9) 2.4	(1.2–5.5) 
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